Denosumab Market Size, Latest Trends, Growth Status, Top Major Players And Forecast To 2033

"The Business Research Company recently released a comprehensive report on the Global Denosumab Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

According to The Business Research Company's, The denosumab market size has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to clinical trials and research advancements, FDA approvals and regulatory milestones, growing awareness of bone health, strategic partnerships and marketing initiatives.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Market Drivers and Trends:

The increasing prevalence of osteoporosis is expected to propel the growth of the denosumab market going forward. Osteoporosis is a medical condition where the bones become weak, resulting in lower bone density and a higher risk of fractures. Denosumab is used to treat osteoporosis by stopping bone resorption through the targeting of the RANK ligand. For instance, In December 2023, according to a report published by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, osteoporosis contributed to 2,366 deaths, or 6.5 deaths per 100,000 population in 2021, representing 1.4% of all deaths. Further, in 2021-22, there were 9,500 hospitalizations with a principal diagnosis of osteoporosis (89 hospitalizations per 100,000 population) for people aged 45 and over. Therefore, the increasing prevalence of osteoporosis is driving the growth of the denosumab market.

Major companies operating in the denosumab market are increasing their focus on introducing innovative solutions, such as first-line treatments for osteoporosis, to gain a competitive edge in the market. First-line treatment for osteoporosis refers to the initial or primary therapeutic approach recommended by healthcare professionals when managing individuals diagnosed with osteoporosis. For instance, in November 2022, Boan Biotech, a China-based biotechnology company, received approval from China's National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, making it the first Chinese company to develop a denosumab injection. It is also being developed for markets outside of China, including Europe and the United States, with plans for global marketing. The drug has been recommended as a first-line treatment for osteoporosis in various treatment guidelines. The medication has the potential to dramatically lower the risk of hip, non-vertebral, and vertebral fractures in this patient population. Additionally, Boyoubei is the first biosimilar to Prolia (the originator of denosumab) approved for marketing in the world.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

Major Key Players of the Market:

Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

Denosumab Market 2024 Key Insights:

• The denosumab market is expected to grow to $5.06 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%.
• Denosumab Market Growth Fueled By Rising Osteoporosis Prevalence
• Emphasis On First-Line Denosumab Treatments For Osteoporosis
• North America was the largest region in the denosumab market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=13835&type=smp"

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.